Glass Pharms Appoints New Chairman to Support Mission of Providing High Quality Medical Cannabis to UK Patients
Wednesday 8 January, 2025 – Glass Pharms, a leading UK-based medical cannabis cultivation company, is pleased to announce the appointment of Adam George as Chairman. George officially joined the board on 1st December 2024.
Glass Pharms’ chief executive, James Duckenfield, expressed his excitement about George’s addition to the team, stating “We are delighted that Adam has joined the board. He brings unparalleled experience in pharmaceutical cannabis, with over 13 years spent at GW Pharmaceuticals including positions of CFO and UK managing director. He will support us in our mission to bring high quality pharmaceutical cannabis products to UK patients.”
With a background in pharmaceutical cannabis, George previously worked at GW Pharmaceuticals, now Jazz Pharmaceuticals, for 13 years before leaving in 2020. He also has other interests in businesses developing medicines derived from or inspired by plants, fungi and other natural sources.
In his statement, George shared his enthusiasm for joining Glass Pharms, saying “It’s an exciting time to join Glass Pharms. With solid foundations laid through a world-class cultivation facility and an excellent team, the business is well-positioned to capitalise on the growing demand for high quality, UK produced, cannabis based medicines.”
Glass Pharms is a UK-based licensed cultivator of cannabis exclusively for the medical supply chain. The company was established to meet patient demand for dependable supply of high quality, UK-produced, cannabis-based medicines at a fair price. To achieve this goal, Glass Pharms uses a patent-pending continuous cultivation system that takes the plants on a 12-week journey through various climate chambers, creating an accelerated simulation of a growing year. This innovative environment uses about 40% of the power compared to traditional indoor growing facilities and is powered by off-grid green energy.
For more information about Glass Pharms, visit their website at https://glasspharms.com/ or contact Mark Heley at info@glasspharms.com.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.